Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Multikine enters Canadian phase I/II trial

July 12, 1996

Antitumor vaccines described by University of Pennsylvania

July 5, 1996

Human Genome Sciences reports discovery of TNF-gamma

July 5, 1996

Virulizin undergoes phase I/II in pancreatic cancer

June 28, 1996

Multikine covered under Japanese patent

June 21, 1996

Actimmune metastatic renal cell carcinoma development terminated

June 14, 1996

E. Merck describes immunoconjugates

June 7, 1996

MuIGIF with interferon gamma production-stimulating properties identified

May 31, 1996

Results of MAb-B1 phase I/II trial announced

May 31, 1996

IMMU-14 demonstrates evidence of activity

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...